Concepedia

Tal Zaks

TZ

41

Publications

6.2K

Citations

28

H-Index

1998

Active since

Affiliations

Moderna Therapeutics (United States)(Current)

GlaxoSmithKline (United States)

National Cancer Institute

UPMC Hillman Cancer Center

Sarah Cannon

Tal Zaks is an author at Moderna Therapeutics (United States) specializing in medicine, immunology, and cancer research.

Top concepts

Publications per year

1998–2024

41

Publications

41

Endogenous oncogenic K-rasG12D stimulates proliferation and widespread neoplastic and developmental defects

David A. Tuveson, Alice T. Shaw, Nicholas A. Willis et al. · Cancer Cell · 2004 · 809 citations · Full text

, , +8

Preclinical and Clinical Demonstration of Immunogenicity by mRNA Vaccines against H10N8 and H7N9 Influenza Viruses

Kapil Bahl, Joe J. Senn, Olga Yuzhakov et al. · Molecular Therapy · 2017 · 646 citations

Individualised neoantigen therapy mRNA-4157 (V940) plus pembrolizumab versus pembrolizumab monotherapy in resected melanoma (KEYNOTE-942): a randomised, phase 2b study

Jeffrey S. Weber, Matteo S. Carlino, Adnan Khattak et al. · The Lancet · 2024 · 598 citations

, , +7

mRNA vaccines against H10N8 and H7N9 influenza viruses of pandemic potential are immunogenic and well tolerated in healthy adults in phase 1 randomized clinical trials

Robert Feldman, Rainard Fuhr, Igor Smolenov et al. · Vaccine · 2019 · 453 citations · Full text

mRNA vaccine–induced neoantigen-specific T cell immunity in patients with gastrointestinal cancer

Gal Cafri, Jared J. Gartner, Tal Zaks et al. · Journal of Clinical Investigation · 2020 · 389 citations · Full text

Rows per page

1–5 of 41